Royalty Pharma Cash Flow Statement
NASDAQ: RPRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Royalty Pharma free cash flow
In fiscal 2025, Royalty Pharma generated $2.49 billion of operating cash flow. That left free cash flow of $2.49 billion, a free-cash-flow margin of 104.7% of revenue. Free cash flow was down 10.1% from the prior year's $2.77 billion.
Royalty Pharma returned $1.23 billion to shareholders through share repurchases, equal to 49% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Royalty Pharma cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Net Income | 1.32B | 1.33B | 1.70B | 230.06M | 1.24B | 1.70B | 2.46B | 1.52B |
| Net Income growth (YoY) | -0.50% | -21.72% | +638.96% | -81.46% | -27.07% | -30.85% | +62.16% | — |
| Depreciation & Amortization | 3.85M | 0 | 0 | — | — | — | — | — |
| Stock-Based Compensation | 289.89M | 2.34M | 2.36M | 2.17M | 2.44M | 5.43M | 0 | 0 |
| Change in Working Capital | -13.93M | -2.29M | 6.24M | 2.29M | -4.59M | -766.00K | 6.50M | 1.35M |
| Operating Cash Flow | 2.49B | 2.77B | 2.99B | 2.14B | 2.02B | 2.03B | 1.67B | 1.62B |
| Investing Cash Flow | -1.61B | -2.68B | -2.07B | -1.03B | -1.87B | -2.76B | -2.15B | 303.42M |
| Share Repurchases | -1.23B | -229.65M | -304.76M | 0 | 0 | 0 | -4.27M | 0 |
| Debt Issued | — | — | — | 0 | 1.27B | 11.89B | 0 | 0 |
| Debt Repaid | — | — | — | 0 | 0 | -11.12B | 0 | 0 |
| Financing Cash Flow | -1.19B | 361.14M | -2.15B | -944.86M | 385.11M | 1.49B | -1.19B | -1.38B |
| Net Change in Cash | -310.33M | 452.02M | -1.23B | 169.70M | 532.37M | 762.48M | -1.68B | 542.64M |
| Free Cash Flow | 2.49B | 2.77B | 2.99B | 2.14B | 2.02B | 2.03B | 1.67B | 1.62B |
This table shows 8 annual periods of Royalty Pharma's cash flow statement, from FY 2025 back to FY 2018, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RPRX's reporting calendar. What is a cash flow statement?